Bringing Light to Life Through Clay Siegall

Seattle Genetics is a biotech company located in Bothell, Washington. They have gained widespread interest for their research and current uses for the drug called ADCETRIS. They recently have announced an increase in their public stock offering from $480 million to an astounding $552 million without showing a profit. The company has made it clear that building the business is far more important than showing an immediate profit. It also helps that they will be expanding the uses of the drug ADCETRIS well beyond just cancer treatments in the near future. They are forecasting increasing their staff from the current count of over 800 employees to approximately 1300 by the year 2020. Dr. Clay Siegall has played a huge part in leading the Seattle Genetics’ initial public offering in 2001 by implementing capital-raising activities and securing more than $1.2 billion through public and private financings.

Dr. Clay B. Siegall, Ph.D. is the the CEO, President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc. He has an extensive background in biotechnology and has worked with research companies, as well as Alder BioPharmaceuticals and Mirna Therapeutics where he actively serves on the board of directors for both companies. Dr. Siegall has spent his lifetime studying science and then researching ways to improve people’s health who are suffering from life altering diseases. He earned a B.S. degree in Zoology from the University of Maryland and then furthered his studies to later earn his Ph.D. in Genetics from George Washington University located in Washington, DC.

Dr. Siegall was the key player in securing the 2011 FDA approval of its first ADC product, ADCETRIS. Which is now approved and available in over 60 countries worldwide, making it a global brand. This has opened the door for advancing a pipeline of proprietary ADCs for the treatment of cancer. He has received a variety of awards which include the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He currently holds 15 patents and has written more than 70 publications.